RecruitingPhase 1NCT07710690
A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Recurrent or Progressive High-grade Glioma
Sponsor
Neuregen Therapeutics Co., Ltd.
Enrollment
24 participants
Start Date
Jul 9, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
The primary objective of this study is to determine the safe dose range of NRG-103 in patients and to recommend the dosage for subsequent treatment, while also evaluating the preliminary efficacy and tolerability of the product.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called NRG-103 for people with hgg, high grade glioma, and other related conditions. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGNRG-103
NRG-103
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07710690
Related Trials
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
NCT052782084 locations
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
NCT074161881 location
MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
NCT067128753 locations
Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases
NCT068888176 locations
Dabrafenib and/or Trametinib Rollover Study
NCT0334050632 locations